GLENMARK - Glenmark Pharmaceuticals

Glenmark Pharmaceuticals

GLENMARK · Pharma > Pharmaceuticals & Drugs · Chairman: Glenn Saldanha · MD: Glenn Saldanha · Listing date: Feb. 9, 2000 · Employees: 10964 · Mumbai · http://www.glenmarkpharma.com

Stock Price vs Company Growth

0.0%

5.4%

12.2%

21.3%

45.2%

96.6%

11.3%

10y

7.0%

all

8.0%

🤔 How to analyze this graph?

Last Traded Price

₹ 1,080 0.0%

767

1,096

Company Overview

Sales

12,489 Cr

Growth: 8.3%

Profit after Tax

-712 Cr

Growth: 485.2%

Large Cap

30,478 Cr

P/S: 2.4x

Industry P/S: 2.6x

Fundamentals

Sales (Cr)	₹ 12,489
Growth	8.3%
EBITDA	11.9%
P/S	2.4x
Dividend	0.3%
P/E	-32.1x
Book Value	₹ 326
PEG Ratio	-3.9x
ROE	-7.5%
P/B	3.3x

Shareholding Pattern

Institutions

Qualified Institutional Buyer

4.74 %

Hsbc Pooled Investment Fund - Hsbc Pooled Asia Pac

3.25 %

Hdfc Trustee Company Ltd. A/C Hdfc Growth Opportunities Fund

2.26 %

Ntasain Discovery Master Fund

2.05 %

Life Insurance Corporation Of India

1.76 %

Promoters

Saldanha Family Trust

45.45 %

Blanche Elizabeth Saldanha

0.39 %

Glenn Mario Saldanha

0.35 %

Cherylann Maria Pinto

0.27 %

Robin Joseph Pinto

0.18 %

Others

Ashish Dhawan

1.81 %

Iepf

0.08 %

Increase Decrease No change

Company Profile Detailed

The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark’s ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain].

Belongs to (24 Indices) view more

Investors (108)

tata.bal...

robin.pi...

oppeheim...

Followers (36)

nitin2

keerthi

deepak